Liraglutide's Glycemic Control Efficacy Compared to Metformin Monotherapy and Metformin/Glimepiride in Type 2 Diabetes
Background
Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction, leading to persistent hyperglycemia. While metformin remains the first-line therapy, many patients eventually require additional agents to achieve target HbA1c levels. Traditional add-on therapies like sulfonylureas (e.g., glimepiride) stimulate insulin secretion but carry risks of hypoglycemia and weight gain. GLP-1 receptor agonists like liraglutide offer an alternative mechanism, enhancing glucose-dependent insulin secretion, suppressing glucagon, and promoting satiety, often with a lower risk of hypoglycemia and potential for weight loss. This Phase 3 trial aimed to rigorously compare liraglutide's efficacy and safety profile in combination with metformin against established therapies.
Study Design
This Phase 3, randomized, double-treatment trial, known as LEAD-2, enrolled 1091 subjects with Type 2 Diabetes who were previously treated with oral hypoglycemic agents. Conducted across Europe and Oceania, the study compared once-daily subcutaneous administration of liraglutide (at 0.6 mg, 1.2 mg, or 1.8 mg) combined with metformin (1.5-2.0 g tablets) against two control arms: metformin monotherapy and a combination of metformin with glimepiride (4 mg tablets). Placebo arms for both liraglutide and glimepiride were included to maintain blinding. The primary endpoint was the effect on glycemic control over the study duration.
Results
The provided trial registration (NCT00318461) details the comprehensive study design and the various intervention arms but does not include specific quantitative results, statistical analyses, or detailed safety findings from the completed trial. Therefore, no specific percentages, p-values, or fold-changes regarding HbA1c reduction, fasting plasma glucose levels, body weight changes, or adverse events can be reported here. The trial was completed in November 2008, and its findings would typically be published in peer-reviewed journals, which are not part of the provided abstract. Without access to the full publication, detailed outcomes cannot be summarized. > The trial aimed to assess the effect of liraglutide added to metformin on glycemic control compared to metformin alone or metformin plus glimepiride in Type 2 Diabetes patients.